Similarities and Differences of Chemical Compositions and Physical and Functional Properties of Adjuvant System 01 and Army Liposome Formulation with QS21

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Feb 10

PMID 36761767

Authors

Carl R Alving

Mangala Rao

Gary R Matyas

Affiliations

Soon will be listed here.

Abstract

A vaccine adjuvant known as Adjuvant System 01 (AS01) consists of liposomes containing a mixture of natural congeners of monophosphoryl lipid A (MPL) obtained from bacterial lipopolysaccharide, and a tree saponin known as QS21. Two vaccines containing AS01 as the adjuvant have been licensed, including a malaria vaccine (Mosquirix) approved by World Health. Organization and European Medicines Agency for use in sub-Saharan Africa, and a shingles vaccine (Shingrix) approved by the U.S. Food and Drug Administration. The success of the AS01 vaccine adjuvant has led to the development of another liposomal vaccine adjuvant, referred to as Army Liposome Formulation with QS21 (ALFQ). Like AS01, ALFQ consists of liposomes containing monophosphoryl lipid A (as a synthetic molecule known as 3D-PHAD) and QS21 as adjuvant constituents, and the polar headgroups of the liposomes of AS01 and ALFQ are similar. We compare here AS01 with ALFQ with respect to their similar and different liposomal chemical structures and physical characteristics with a goal of projecting some of the likely mechanisms of safety, side effects, and mechanisms of adjuvanticity. We hypothesize that some of the side effects exhibited in humans after injection of liposome-based vaccines might be caused by free fatty acid and lysophospholipid released by enzymatic attack of liposomal phospholipid by phospholipase A at the injection site or systemically after injection.

Citing Articles

Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.

Korompis M, De Voss C, Li S, Richard A, Salman Almujri S, Ateere A Sci Rep. 2025; 15(1):1886.

PMID: 39805855 PMC: 11729893. DOI: 10.1038/s41598-024-84667-8.

Post-Marketing Surveillance of Adverse Events for the Recombinant Zoster Vaccine Among the Population over 50 Years Old in Hangzhou, China.

Wang J, Du J, Liu Y, Xu Y, Han J, Zhang X Vaccines (Basel). 2025; 12(12.

PMID: 39772038 PMC: 11680005. DOI: 10.3390/vaccines12121376.

Development of a New Vaccine Adjuvant System Based on the Combination of the Synthetic TLR4 Agonist FP20 and a Synthetic QS-21 Variant.

Shaik M, Pasco S, Romerio A, Pifferi C, Sesana S, Re F J Med Chem. 2024; 67(24):22254-22262.

PMID: 39645607 PMC: 11684016. DOI: 10.1021/acs.jmedchem.4c02392.

Development of semisynthetic saponin immunostimulants.

Bai D, Kim H, Wang P Med Chem Res. 2024; 33(8):1292-1306.

PMID: 39132259 PMC: 11315725. DOI: 10.1007/s00044-024-03227-x.

Vaccine adjuvants for infectious disease in the clinic.

Goetz M, Thotathil N, Zhao Z, Mitragotri S Bioeng Transl Med. 2024; 9(4):e10663.

PMID: 39036089 PMC: 11256182. DOI: 10.1002/btm2.10663.

References

Sei C, Rao M, Schuman R, Daum L, Matyas G, Rikhi N . Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies. Vaccines (Basel). 2021; 9(7). PMC: 8310080. DOI: 10.3390/vaccines9070698. View

Marciani D . Is fucose the answer to the immunomodulatory paradox of Quillaja saponins?. Int Immunopharmacol. 2015; 29(2):908-913. DOI: 10.1016/j.intimp.2015.10.028. View

Cochet F, Peri F . The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling. Int J Mol Sci. 2017; 18(11). PMC: 5713287. DOI: 10.3390/ijms18112318. View

Burny W, Marchant A, Herve C, Callegaro A, Caubet M, Fissette L . Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. Vaccine. 2019; 37(14):2004-2015. DOI: 10.1016/j.vaccine.2019.02.015. View

Hagar J, Powell D, Aachoui Y, Ernst R, Miao E . Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science. 2013; 341(6151):1250-3. PMC: 3931427. DOI: 10.1126/science.1240988. View

Seu K, Cambrea L, Everly R, Hovis J . Influence of lipid chemistry on membrane fluidity: tail and headgroup interactions. Biophys J. 2006; 91(10):3727-35. PMC: 1630490. DOI: 10.1529/biophysj.106.084590. View

Paepenmuller T, Muller-Goymann C . Influence of Quil A on liposomal membranes. Int J Pharm. 2014; 475(1-2):138-46. DOI: 10.1016/j.ijpharm.2014.08.007. View

Maeshima N, Fernandez R . Recognition of lipid A variants by the TLR4-MD-2 receptor complex. Front Cell Infect Microbiol. 2013; 3:3. PMC: 3569842. DOI: 10.3389/fcimb.2013.00003. View

Jett M, Alving C . Tumoricidal effects of liposomes containing phosphatidylinositol or phosphatidylcholine. Methods Enzymol. 1987; 141:459-66. DOI: 10.1016/0076-6879(87)41092-6. View

10.

Alving C, Rao M, Steers N, Matyas G, Mayorov A . Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines. 2012; 11(6):733-44. DOI: 10.1586/erv.12.35. View

11.

Dennis E . Allosteric regulation by membranes and hydrophobic subsites in phospholipase A enzymes determine their substrate specificity. J Biol Chem. 2022; 298(5):101873. PMC: 9079178. DOI: 10.1016/j.jbc.2022.101873. View

12.

Beck Z, Matyas G, Jalah R, Rao M, Polonis V, Alving C . Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015; 33(42):5578-5587. DOI: 10.1016/j.vaccine.2015.09.001. View

13.

Lacaille-Dubois M . Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review. Phytomedicine. 2019; 60:152905. PMC: 7127804. DOI: 10.1016/j.phymed.2019.152905. View

14.

Alving C, Peachman K, Matyas G, Rao M, Beck Z . Army Liposome Formulation (ALF) family of vaccine adjuvants. Expert Rev Vaccines. 2020; 19(3):279-292. PMC: 7412170. DOI: 10.1080/14760584.2020.1745636. View

15.

Bangham A, HORNE R, GLAUERT A, DINGLE J, LUCY J . Action of saponin on biological cell membranes. Nature. 1962; 196:952-5. DOI: 10.1038/196952a0. View

16.

Rao M, Onkar S, Peachman K, White Y, Trinh H, Jobe O . Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans. J Infect Dis. 2018; 218(10):1541-1550. DOI: 10.1093/infdis/jiy348. View

17.

Marty-Roix R, Vladimer G, Pouliot K, Weng D, Buglione-Corbett R, West K . Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants. J Biol Chem. 2015; 291(3):1123-36. PMC: 4714196. DOI: 10.1074/jbc.M115.683011. View

18.

Singh P, Beck Z, Matyas G, Alving C . Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition. J Liposome Res. 2018; 29(3):247-250. DOI: 10.1080/08982104.2018.1538239. View

19.

Hutter J, Robben P, Lee C, Hamer M, Moon J, Merino K . First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults. Vaccine. 2022; 40(40):5781-5790. DOI: 10.1016/j.vaccine.2022.08.048. View

20.

McElrath M . Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol. 1995; 6(6):375-85. DOI: 10.1016/1044-579x(95)90007-1. View